Cell and Organ Transplantology. 2016; 4(1):10-13.
Effect of transplantation of cord blood total nucleated cells on the manifestation and prognosis of refractory congestive heart failure
Usenko O. Yu., Yakushev A. V., Kostylyev M. V., Onischenko V. F.
Shalimov National Institute of Surgery and Transplantology NAMS of Ukraine, Kyiv, Ukraine
The results of a prospective non-randomized observation study without control group to assess the course of heart failure in patients who underwent of cord blood total nucleated cells (CB TNCs) transplantation combined with traditional drug therapy have been presented.
Materials. The study included 20 patients with congestive heart failure (CHF) IIA-IIB stage, functional class III-IV by the NYHA. CB TNCs transplantation was performed by a single intravenous dose of cell product “Cryopreserved human cord blood”. Before and 1, 3, 6 and 9 months after CB TNC transplantation patients underwent echocardiographic study, the results of tests with the 6-minute walk determined exercise tolerance. The concentration of brain natriuretic peptide precursor (NT-proBNP) in blood was determined. The cardiovascular death risk was calculated using the scale MAGGIC.
Results. Initial patients’ status was characterized by the presence of severe heart failure with reduced contractility of the myocardium and increased risk of 1- and 3-year death. Traditional conservative therapy (beta blockers, ACE inhibitors, diuretics) was not effective. After CB TNC transplantation there was registered a significant improvement of general condition of patients, an increase in exercise tolerance and, therefore, reduce of HF functional class by NYHA (before transplantation average FC was 3.2, in the post-transplant period – from 2.1 to 2, 8). Also after TNCs transplantation levels of biochemical markers of HF significantly decreased (before CB TNCs transplantation the level of NT-proBNP was 2370.3 ± 448.9 pg/mL, after CB TNCs transplantation – from 1198,6 ± 396,3 to 2300,7 ± 403,0 pg/mL ) and the same was estimated death risk from HF (1-year – 10.1-37.4 %, 3 years – 9.1-42.3 % relative to the data of the initial state). Reduced HF manifestations after CB TNCs transplantation allowed to reduce significantly the diuretics dose.
Conclusion. Thus, transplantation of cord blood total nucleated cells in complex treatment of congestive heart failure has led to a greater efficiency of therapy and a significant reduce of CHF manifestations in patients.
Key words: heart failure, nucleated cord blood cells, cell transplantationFull Text PDF (eng) Full Text PDF (ua)
|1. Braunwald E. Heart failure. J Am Coll Cardiol. 2013; 1: 1–20.
|2. Filippatos G, Farmakis D, Parissis J, et al. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med. 2015; 13: 35.
|3. Gheorghiade M, Filippatos G, Felker GM. Diagnosis and management of acute heart failure syndromes. In: Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 9. Philadelphia: Elsevier; 2012, pp. 517-42.
|4. Hofmann R. First outline and baseline data of a randomized, controlled multicenter trial to evaluate the health economic impact of home telemonitoring in chronic heart failure – CardioBBEAT. Trials. 2015; 16: 343.
|5. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Amer Soc Echocardiography. 2015; 28(1): 1-39.
|6. Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report—2013; Focus Theme: Age. The Journal of Heart and Lung Transplantation. 2013; 32(10): 951-64.
|7. McMurray JJV, Aamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012; 33: 1787-847.
|8. Neumann T, Biermann J, Neumann A, et al. Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspective. Dtsch Arztebl Int. 2009; 106: 269-75.
|9. Pereira T, Ivanova G, Caseiro AR, et al. MSCs Conditioned Media and Umbilical Cord Blood Plasma Metabolomics and Composition. PLoS One. 2014; 9(11): e113769.
|10. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies on behalf of the Meta–Analysis Global Group in Chronic Heart Failure (MAGGIC). Eur. Heart. J. 2012; 34(19): 1404-13.
|11. Roe AT, Frisk M, Louch WE. Targeting Cardiomyocyte Ca2+ Homeostasis in Heart Failure. Curr Pharm Des. 2015; 21(4): 431-48.
|12. Salvadori M, Bertoni E. What’s new in clinical solid organ transplantation by 2013. World J Transplant. 2014; 4(4): 243-66.
|13. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128: e240-e327.
Usenko OYu, Yakushev AV, Kostylyev MV, Onischenko VF. Effect of transplantation of cord blood total nucleated cells on the manifestation and prognosis of refractory congestive heart failure. Cell and Organ Transplantology. 2016; 4(1):10-13. doi: 10.22494/COT.V4I1.6